Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial
Year: 2022
Type: article
Study design: Clinical Trial
Source: The Lancet Haematology
Authors: Sagar Lonial, Rakesh Popat, Cyrille Hulin, Sundar Jagannath, Albert Oriol, Paul G Richardson, Thierry Facon, Katja Weisel, Jeremy T Larsen, Monique C Minnema, Al-Ola Abdallah, Ashraf Z Badros, Stefan Knop, Edward A Stadtmauer, Yiming Cheng, Michael Amatangelo, Min Chen, Tuong Vi Nguyen, Alpesh Amin, Teresa Peluso, Niels W C J van de Donk
Institutions: Emory University, Winship Cancer Institute, University College London Hospitals NHS Foundation Trust, Centre Hospitalier Universitaire de Bordeaux, Mount Sinai Hospital, Dana-Farber Cancer Institute, Centre Hospitalier Universitaire de Lille, Hôpital Claude Huriez, University Medical Center Hamburg-Eppendorf, Mayo Clinic in Arizona, University Medical Center Utrecht, University of Kansas Medical Center, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Universitätsklinikum Würzburg, University of Pennsylvania, Bristol-Myers Squibb (United States), Amsterdam University Medical Centers, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4302759581